Works matching DE "VENETOCLAX"

Results: 540
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial.

    Published in:
    Basic & Clinical Pharmacology & Toxicology, 2025, v. 136, n. 6, p. 1, doi. 10.1111/bcpt.70041
    By:
    • Kytölä, Sari;
    • Kurkela, Mika;
    • Kiiski, Johanna I.;
    • Vänttinen, Ida;
    • Ruokoranta, Tanja;
    • Partanen, Anu;
    • Holopainen, Annasofia;
    • Pyörälä, Marja;
    • Kuusisto, Milla E. L.;
    • Siitonen, Timo;
    • Koskela, Sirpa;
    • Rimpiläinen, Johanna;
    • Ettala, Pia;
    • Kuusanmäki, Heikki;
    • Niemi, Mikko;
    • Backman, Janne T.;
    • Kontro, Mika
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax.

    Published in:
    Clinical Epigenetics, 2024, v. 16, n. 1, p. 1, doi. 10.1186/s13148-024-01658-2
    By:
    • Li, Danyang;
    • Yuan, Yigang;
    • Meng, Chen;
    • Lin, Zihan;
    • Zhao, Min;
    • Shi, Liuzhi;
    • Li, Min;
    • Ye, Daijiao;
    • Cai, Yue;
    • He, Xiaofei;
    • Ye, Haige;
    • Zhou, Shujuan;
    • Zhou, Haixia;
    • Gao, Shenmeng
    Publication type:
    Article
    25
    26
    27
    28

    Recommendations on the use of azole antifungals in hematology-oncology patients.

    Published in:
    Revista Española de Quimioterapia, 2023, v. 36, n. 3, p. 236, doi. 10.37201/req/013.2023
    By:
    • Ramón Azanza, José;
    • Mensa, José;
    • Barberán, José;
    • Vázquez, Lourdes;
    • Pérez de Oteyza, Jaime;
    • Kwon, Mi;
    • Yáñez, Lucrecia;
    • María Aguado, José;
    • Cubillo Gracian, Antonio;
    • Solano, Carlos;
    • Ruiz Camps, Isabel;
    • Fortún, Jesús;
    • Lletí, Miguel Salavert;
    • Gudiol, Carlota;
    • Olave Rubio, Teresa;
    • García-Vidal, Carolina;
    • Rovira Tarrats, Montserrat;
    • Suárez-Lledó Grande, María;
    • González-Sierra, Pedro;
    • Dueñas Gutiérrez, Carlos
    Publication type:
    Article
    29
    30
    31
    32

    Prescription patterns of venetoclax in acute myeloid leukemia.

    Published in:
    Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3298
    By:
    • Ucciero, Andrealuna;
    • Traversa, Giuseppe;
    • Pisterna, Alessia;
    • Cardinali, Valeria;
    • Sciabolacci, Sofia;
    • Poloni, Antonella;
    • Capelli, Debora;
    • Gaidano, Gianluca;
    • Patriarca, Andrea;
    • Lunghi, Monia
    Publication type:
    Article
    33

    A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.

    Published in:
    Hematological Oncology, 2024, v. 42, n. 3, p. 1, doi. 10.1002/hon.3274
    By:
    • Manda, Sudhir;
    • Anz, Bertrand M.;
    • Benton, Christopher;
    • Broun, E. Randolph;
    • Yimer, Habte A.;
    • Renshaw, John S.;
    • Geils, George;
    • Berdeja, Jesus;
    • Cruz, Jose;
    • Melear, Jason M.;
    • Fanning, Suzanne;
    • Fletcher, Luke;
    • Li, Yukun;
    • Duan, Yinghui;
    • Werner, Michael E.;
    • Potluri, Jalaja;
    • Pai, Madhavi V.;
    • Donnellan, William B.
    Publication type:
    Article
    34
    35
    36
    37

    Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.

    Published in:
    Hematological Oncology, 2023, v. 41, n. 5, p. 877, doi. 10.1002/hon.3199
    By:
    • Autore, Francesco;
    • Innocenti, Idanna;
    • Reda, Gianluigi;
    • Visentin, Andrea;
    • Vitale, Candida;
    • Piciocchi, Alfonso;
    • Fresa, Alberto;
    • Leone, Monica M. A.;
    • Farina, Lucia;
    • Quaresmini, Giulia;
    • Baratè, Claudia;
    • Giordano, Annamaria;
    • Ferrari, Angela;
    • Angeletti, Ilaria;
    • De Paolis, Maria Rosaria;
    • Malerba, Lara;
    • Chiurazzi, Federico;
    • Loseto, Giacomo;
    • Catania, Gioacchino;
    • Sportoletti, Paolo
    Publication type:
    Article
    38
    39
    40
    41
    42

    A PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX COMPARED TO OBINUTUZUMAB AND VENETOCLAX IN PATIENTS WITH HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 851, doi. 10.1002/hon.3166_OT30
    By:
    • Kutsch, N.;
    • Fink, A. M.;
    • Robrecht, S.;
    • Tausch, E.;
    • Schneider, C.;
    • Dierks, C.;
    • Wendtner, C.;
    • Meyer, R.;
    • Gaska, T.;
    • Chakupurakal, G.;
    • Jentsch‐Ullrich, K.;
    • Steiniger, H.;
    • Schwaner, I.;
    • Neumann, C.;
    • Fischer, K.;
    • Kreuzer, K.;
    • Ritgen, M.;
    • Stilgenbauer, S.;
    • Hallek, M.;
    • Eichhorst, B.
    Publication type:
    Article
    43
    44
    45
    46
    47
    48

    Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 582, doi. 10.1002/hon.3164_437
    By:
    • Melani, C. J.;
    • Lakhotia, R.;
    • Pittaluga, S.;
    • Phelan, J. D.;
    • Yang, Y.;
    • Davies‐Hill, T.;
    • Simard, J.;
    • Muppidi, J.;
    • Huang, D. W.;
    • Thomas, C. J.;
    • Ceribelli, M.;
    • Tosto, F. A.;
    • Pradhan, A.;
    • Juanitez, A. M.;
    • Rimsza, L. M.;
    • Jacob, A.;
    • Simmons, H.;
    • Steinberg, S. M.;
    • Jaffe, E. S.;
    • Staudt, L. M.
    Publication type:
    Article
    49
    50